Closure, price control & hope of growth

| Updated on January 16, 2018

The year ends with a mixed bag of fortunes for the pharmaceutical and medical technology industry. While the stage is set for Government to exercise price control on stents (devices used to remove blockages in heart procedures), the Delhi High Court has quashed an earlier ban by the Government on 344 combination drugs. Both situations could go into another round of litigation or long drawn out discussions that delay the outcome for the patient. Late December will also see Sandoz discontinue its Turbhe site (Maharashtra), as part of a global strategy to optimize manufacturing.

As for 2017, the med-tech industry will have to cope with life under a price control regime, even as the pharma world is optimistic of an improvement in its growth trajectory.

Published on December 24, 2016

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

This article is closed for comments.
Please Email the Editor